Safety of LEQEMBI in people with Alzheimer's disease in Taiwan
Observes side effects and disease progression in people with Alzheimer's disease treated with LEQEMBI.
Plain-language title generated from the registry record
Registry title: An Observational Study of LEQEMBI in Routine Clinical Practice in Taiwan
Key facts
- Where
- Kaohsiung City, New Taipei City, Taichung, Tainan, Taipei, and Taoyuan, TaiwanSee the 12 sites
Where in Taiwan
- Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial HospitalKaohsiung City, TaiwanNo longer taking part
- Cardinal Tien HospitalNew Taipei City, TaiwanNo longer taking part
- En Chu Kong HospitalNew Taipei City, TaiwanNo longer taking part
- Far Eastern Memorial HospitalNew Taipei City, TaiwanNo longer taking part
- New Taipei Municipal TuCheng HospitalNew Taipei City, TaiwanNo longer taking part
- Taipei Medical University Shuang Ho HospitalNew Taipei City, TaiwanNo longer taking part
- Chung Shan Medical University HospitalTaichung, TaiwanNo longer taking part
- National Cheng Kung University HospitalTainan, TaiwanNo longer taking part
- Mackay Memorial Hospital-Taipei branchTaipei, TaiwanNo longer taking part
- National Taiwan University HospitalTaipei, TaiwanNo longer taking part
- Taipei Veterans General HospitalTaipei, TaiwanNo longer taking part
- Chang Gung Memorial Hospital, LinkouTaoyuan, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eisai Taiwan Inc.
- Trial code
- NCT07869264
- Record updated
- 9 October 2026
- Original description
The primary purpose of this study is to describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities (ARIA)-oedema/effusion (ARIA-E), ARIA-microhemorrhage and haemosiderin deposit (ARIA-H), intracerebral hemorrhage greater than 1 cm, and anaphylaxis (stratified by apolipoprotein E4 variant [APOE4] genotype, concomitant antithrombotic therapy, and comorbid cerebral amyloid angiopathy [CAA]), in participants treated with LEQEMBI in routine clinical practice in Taiwan.Read full original descriptionShow less
An Observational Registry Study to Evaluate the Use and Safety of LEQEMBI in Routine Clinical Practice in Taiwan
The primary purpose of this study is to describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities (ARIA)-oedema/effusion (ARIA-E), ARIA-microhemorrhage and haemosiderin deposit (ARIA-H), intracerebral hemorrhage greater than 1 cm, and anaphylaxis (stratified by apolipoprotein E4 variant [APOE4] genotype, concomitant antithrombotic therapy, and comorbid cerebral amyloid angiopathy [CAA]), in participants treated with LEQEMBI in routine clinical practice in Taiwan.
To describe previously unknown adverse events related to long-term safety of LEQEMBI in routine clinical practice, which were not identified in clinical development, as assessed by serious suspected adverse reactions and adverse reactions leading to discontinuation of LEQEMBI treatment.
To describe progression to the next stage of Alzheimer's Disease (AD) in routine clinical practice.
To describe drug utilization of LEQEMBI and effectiveness of risk minimization measures in routine clinical practice.
Inclusion: Participants with Alzheimer's Disease who are prescribed LEQEMBI in Taiwan; Participants who have been prescribed LEQEMBI and who consent to enroll in the program.
Exclusion: None.